Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns
Shares of Fulcrum Therapeutics plunged 50% in premarket trading on Tuesday after the company said it would abandon development of its experimental sickle-cell disease drug following
June 02, 2026
Bosnia seeks new peace envoy after sudden Schmidt exit
Strain grows on shipping industry with vessels stuck inside Hormuz
US asset managers fall as investors brace for updates on private credit fund withdrawals
Romania says allies preparing to bolster air defences after Russian drone strike
Many airlines hit hard by jet fuel price swings, not all can hedge, IATA says
Officer saves boy from drowning at pond